![Stimulant Equivalency Table --- Matt Swenson, MD / stimulant-equivalency-table-matt-swenson-md.pdf / PDF4PRO Stimulant Equivalency Table --- Matt Swenson, MD / stimulant-equivalency-table-matt-swenson-md.pdf / PDF4PRO](https://pdf4pro.com/cache/preview/5/0/0/a/3/5/d/f/thumb-500a35df6c8c03106302c999042fd3e9.jpg)
Stimulant Equivalency Table --- Matt Swenson, MD / stimulant-equivalency-table-matt-swenson-md.pdf / PDF4PRO
![Z-Score Neurofeedback and Heart Rate Variability Training for Adults and Children with Symptoms of Attention-Deficit/Hyperactivity Disorder: A Retrospective Study | SpringerLink Z-Score Neurofeedback and Heart Rate Variability Training for Adults and Children with Symptoms of Attention-Deficit/Hyperactivity Disorder: A Retrospective Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10484-019-09439-x/MediaObjects/10484_2019_9439_Fig3_HTML.png)
Z-Score Neurofeedback and Heart Rate Variability Training for Adults and Children with Symptoms of Attention-Deficit/Hyperactivity Disorder: A Retrospective Study | SpringerLink
![Stimulant Equivalency Table --- Matt Swenson, MD / stimulant-equivalency-table-matt-swenson-md.pdf / PDF4PRO Stimulant Equivalency Table --- Matt Swenson, MD / stimulant-equivalency-table-matt-swenson-md.pdf / PDF4PRO](https://pdf4pro.com/cache/preview/5/c/4/8/9/1/1/6/thumb-5c489116a3f3229b8208409055015867.jpg)
Stimulant Equivalency Table --- Matt Swenson, MD / stimulant-equivalency-table-matt-swenson-md.pdf / PDF4PRO
![Comparative efficacy of Concerta®(18, 36 mg) and Ritalin LA®(20 mg)... | Download Scientific Diagram Comparative efficacy of Concerta®(18, 36 mg) and Ritalin LA®(20 mg)... | Download Scientific Diagram](https://www.researchgate.net/profile/Antonella-Gagliano-2/publication/257202727/figure/fig3/AS:202535299227650@1425299586196/Comparative-efficacy-of-ConcertaR18-36mg-and-Ritalin-LAR20mg-versus-placebo-in-a_Q640.jpg)
Comparative efficacy of Concerta®(18, 36 mg) and Ritalin LA®(20 mg)... | Download Scientific Diagram
![Mixed amphetamine salts extended release: a clinical review of its use in the treatment of attention-deficit hyperactivity disorder | Future Neurology Mixed amphetamine salts extended release: a clinical review of its use in the treatment of attention-deficit hyperactivity disorder | Future Neurology](https://www.futuremedicine.com/cms/10.2217/14796708.1.5.525/asset/images/medium/graphic22.gif)
Mixed amphetamine salts extended release: a clinical review of its use in the treatment of attention-deficit hyperactivity disorder | Future Neurology
![MTS abrupt conversion study design. MTS = methylphenidate transdermal... | Download Scientific Diagram MTS abrupt conversion study design. MTS = methylphenidate transdermal... | Download Scientific Diagram](https://www.researchgate.net/profile/Paul-Hodgkins/publication/40681125/figure/fig2/AS:289285476503556@1445982440459/MTS-abrupt-conversion-study-design-MTS-methylphenidate-transdermal-system-MPH.png)
MTS abrupt conversion study design. MTS = methylphenidate transdermal... | Download Scientific Diagram
Full article: Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study
![A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial - Clinical Therapeutics A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/634f1049-4f74-41b4-98b9-d2bccca4ac64/gr2_lrg.jpg)
A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial - Clinical Therapeutics
![WO2015188092A1 - Methods for treating attention deficit hyperactivity disorder with methylphenidate - Google Patents WO2015188092A1 - Methods for treating attention deficit hyperactivity disorder with methylphenidate - Google Patents](https://patentimages.storage.googleapis.com/8c/1e/62/9a977f321196c6/imgf000028_0001.png)
WO2015188092A1 - Methods for treating attention deficit hyperactivity disorder with methylphenidate - Google Patents
![Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions | CNS Spectrums | Cambridge Core Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210622083539525-0708:S1092852919001822:S1092852919001822_tab3.png?pub-status=live)
Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions | CNS Spectrums | Cambridge Core
![Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-244X-13-237/MediaObjects/12888_2013_Article_1428_Fig5_HTML.jpg)